Antifungal Therapeutic Drug Monitoring Practices: Results of an Emerging Infections Network Survey
Kaitlin Benedict, Jeremy A.W. Gold, Susan E. Beekmann, Philip M. Polgreen, Mitsuru Toda, Dallas J. Smith
Abstract
In a survey of 523 infectious disease specialists, a moderate to high percentage reported using any antifungal therapeutic drug monitoring (TDM) during itraconazole (72%), posaconazole (72%), and voriconazole (90%) treatment, and a low to moderate percentage reported using any antifungal TDM during prophylaxis (32%, 55%, and 65%, respectively). Long turnaround times for send-out TDM testing and logistical difficulties were frequent barriers.
Topics & Concepts
PosaconazoleMedicineVoriconazoleTherapeutic drug monitoringItraconazoleAntifungalDrugIntensive care medicinePharmacologyDermatologyAntifungal resistance and susceptibilityFungal Infections and StudiesNail Diseases and Treatments